The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

USA News Group News Commentary – The integration of artificial intelligence (AI) into the healthcare sector is accelerating at an unprecedented pace. One of the latest milestones ...

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

The Food and Drug Administration on Monday granted its first approval for a pacemaker-like device for the brain to ease ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

Truist Financial analyst Richard Newitter maintained a Hold rating on Medtronic (MDT – Research Report) on February 23 and set a price target ...